Real-time insights. Smarter decisions. Better trades.
🔍 Search StocksConfidence: 45%
Date: 18-05-2026
Price: $0.033
Last Price: $0.032
Post-Signal Peak Price: $0.032
Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for fiscal year 2025. It stated that much of the growth was due to robust sales of its flagship travele
Shares of Immuron Ltd. rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use. Trading volume spiked to 1.3 million
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR
Chart available once enough post-signal price data is available.
AI Confidence - 45 % model confidence
Immunuron Limited is a clinical-stage biopharmaceutical company focused on developing oral immunotherapy products for gastrointestinal and inflammatory diseases. It operates in a niche market targeting conditions such as ulcerative colitis and COVID-19 related complications, leveraging proprietary antibody technology to modulate immune responses.
| Cash Flow | Weak |
| Debt | Moderate |
| Profitability | Weak |
| Revenue Trend | Downtrend |
| Trend | Bullish |
| Momentum | Moderate |
| RSI Signal | Neutral |
| Support Level | $ 0.0300 |
| Resistance Level | $ 0.0400 |